Trials / Completed
CompletedNCT02016729
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 Alone and in Combination With Trametinib in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Kartos Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 232 | Given an an oral tablet in escalating doses. |
| DRUG | Trametinib | Trametinib is an oral tablet given in a fixed dose. |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2017-04-19
- Completion
- 2017-07-31
- First posted
- 2013-12-20
- Last updated
- 2019-02-27
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02016729. Inclusion in this directory is not an endorsement.